Trials / Recruiting
RecruitingNCT06697197
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 413 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986482 | Specified dose on specified days |
| DRUG | Nivolumab and rHuPH20 | Specified dose on specified days |
| DRUG | Nivolumab/relatlimab/rHuPH20 | Specified dose on specified days |
| DRUG | Bevacizumab | Specified dose on specified days |
Timeline
- Start date
- 2025-02-17
- Primary completion
- 2029-01-04
- Completion
- 2029-01-05
- First posted
- 2024-11-20
- Last updated
- 2026-02-03
Locations
21 sites across 9 countries: United States, Belgium, Denmark, France, Greece, Italy, Netherlands, Spain, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06697197. Inclusion in this directory is not an endorsement.